Q-omics provides the consensus-scored TAS1R3 profile across patient tissues and cancer cell-line models. TAS1R3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TAS1R3 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, TAS1R3 RNA expression shows 13,453 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, LUAD, and TGCT as cancer lineages where TAS1R3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAS1R3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAS1R3 survival associations across molecular data types. TAS1R3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAS1R3 RNA expression–survival associations across cancer types. High TAS1R3 expression shows unfavorable associations in KIRC, but favorable associations in HNSC, SKCM, UVM, LUAD and ACC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TAS1R3 RNA expression.
This table summarizes TAS1R3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TAS1R3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAS1R3 shows lower tumor expression in HNSC and higher tumor expression in LUAD, BLCA, BRCA, THCA and LUSC. The LUAD box plot shows higher TAS1R3 RNA expression in tumor versus normal tissue (log2 FC = +1.186, t-test p < 0.001).
This table shows molecular features associated with TAS1R3 in patient tissues and cancer cell lines. In patient samples, TAS1R3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TAS1R3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
